Difference between revisions of "Crenolanib (CP-868,596)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Investigational" to "Category:Investigational drugs") |
Warner-admin (talk | contribs) m (Text replacement - "3 PubMed]" to "3/ PubMed]") |
||
(6 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
− | + | ==Mechanism of action== | |
+ | From the NCI Drug Dictionary: An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation. | ||
− | =Preliminary Data= | + | ==Preliminary Data== |
− | # Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. [ | + | # Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. [https://doi.org/10.1200/jco.2009.21.8487 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2773478/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19738123/ PubMed] |
+ | |||
+ | ==Also known as== | ||
+ | *'''Code name:''' CP-868-596 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
+ | [[Category:Oral medications]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
− | + | ||
[[Category:FLT3 inhibitors]] | [[Category:FLT3 inhibitors]] | ||
[[Category:PDGFR inhibitors]] | [[Category:PDGFR inhibitors]] |
Latest revision as of 23:13, 26 April 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation.
Preliminary Data
- Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. link to original article link to PMC article PubMed
Also known as
- Code name: CP-868-596